RNA-seq analysis from other studies with enitociclib (39) and AZD4573 (40) treatment of CLL and DLBCL cell lines respectively have shown that ZPF36, JUNB, BTG1, and PIM3 are key DEGs with CDK9 inhibition. This evidence concerns the gene CDK9 and diffuse large B-cell lymphoma.